Frontiers in pharmacology · 2026
Impact of an antimicrobial stewardship-based infection prevention bundle on postoperative central nervous system infection in a tertiary neurosurgery department: a quasi-experimental study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Yuan, Chang Binge, Wang Huanyu, Zhang Yi, Ren Haixia
Аннотация
BACKGROUND: Antimicrobial stewardship integration into infection prevention bundles remains inadequately addressed in neurosurgery.
AIM: To evaluate the impact of an antimicrobial stewardship-based infection prevention bundle on postoperative central nervous system infection (PCNSI) incidence, antibiotic use density (AUD), and consumption of vancomycin and meropenem.
METHODS: A quasi-experimental before-and-after study compared 6-month periods before and after implementation. The bundle comprised perioperative optimization, infection control enhancements, surgical site and drainage management, microbiological stewardship, and antimicrobial stewardship components.
RESULTS: A total of 1,535 patients were analyzed (782 pre-intervention period, 753 post-intervention period). Surgical case-mix shifted significantly, with increased neurotrauma (15.73%-23.37%) and decreased cerebrovascular (45.40%-39.84%) and CSF/hydrocephalus (6.14%-2.79%) procedures. Overall PCNSI incidence decreased from 2.81% to 1.86% [0.654 (95% CI: 0.332-1.289); P = 0.217]. Neurotrauma-specific PCNSI declined from 5.69% to 1.14% [0.190 (95% CI: 0.039-0.933); unadjusted P = 0.035], but it did not remain significant after correction for multiple comparisons. Monthly AUD decreased by 12.0% (P = 0.022). Vancomycin and meropenem consumption decreased by approximately 55% across all metrics (all P < 0.05), with large to very large effect sizes (Cohen's d = 1.561-2.604).
CONCLUSION: The bundle was associated with significant reductions in special-use antimicrobial consumption, supporting practical implications for resistance mitigation and safety. The overall PCNSI decrease was not statistically significant. These findings are consistent with potential intervention benefit, pending validation in adequately powered prospective studies.
AIM: To evaluate the impact of an antimicrobial stewardship-based infection prevention bundle on postoperative central nervous system infection (PCNSI) incidence, antibiotic use density (AUD), and consumption of vancomycin and meropenem.
METHODS: A quasi-experimental before-and-after study compared 6-month periods before and after implementation. The bundle comprised perioperative optimization, infection control enhancements, surgical site and drainage management, microbiological stewardship, and antimicrobial stewardship components.
RESULTS: A total of 1,535 patients were analyzed (782 pre-intervention period, 753 post-intervention period). Surgical case-mix shifted significantly, with increased neurotrauma (15.73%-23.37%) and decreased cerebrovascular (45.40%-39.84%) and CSF/hydrocephalus (6.14%-2.79%) procedures. Overall PCNSI incidence decreased from 2.81% to 1.86% [0.654 (95% CI: 0.332-1.289); P = 0.217]. Neurotrauma-specific PCNSI declined from 5.69% to 1.14% [0.190 (95% CI: 0.039-0.933); unadjusted P = 0.035], but it did not remain significant after correction for multiple comparisons. Monthly AUD decreased by 12.0% (P = 0.022). Vancomycin and meropenem consumption decreased by approximately 55% across all metrics (all P < 0.05), with large to very large effect sizes (Cohen's d = 1.561-2.604).
CONCLUSION: The bundle was associated with significant reductions in special-use antimicrobial consumption, supporting practical implications for resistance mitigation and safety. The overall PCNSI decrease was not statistically significant. These findings are consistent with potential intervention benefit, pending validation in adequately powered prospective studies.